Shares of Teradyne (TER) are down approximately 14% in Wednesday's session, sliding from a prior close of $380.13 to trade near $327, in a classic "beat and guide lower" earnings reaction. Primary catalyst: While Q1 2026 results were a blowout — revenue up 87% year-over-year to a record $1.282 billion and non-GAAP EPS of $2.56 beating consensus by 21% — management's Q2 2026 guidance signaled a meaningful sequential decline.

Shares of Robinhood Markets (HOOD) are down approximately 11% in Wednesday's session, trading near $73.04 after closing at $82.07 on April 28, 2026. Primary catalyst: Q1 2026 earnings, reported after the close on April 28, missed Wall Street consensus on both revenue and Adjusted EBITDA.

LRCX surged +18% over the past 30 days, primarily driven by a strong Q3 fiscal 2026 earnings beat on April 22, with revenue up 24% year-over-year. Over the past quarter, LRCX gained +9%, reflecting broader semiconductor sector strength amid AI-driven demand for advanced chip manufacturing equipment.

ICHR surged +58% over the past 30 days, driven by strong momentum in the semiconductor equipment sector and analyst upgrades. The stock climbed +99% over the past quarter, reflecting a broader recovery in wafer fabrication equipment (WFE) spending and AI-related demand.

Analysts expect Q1 2026 revenue of $15.91 billion, up slightly from $15.5 billion in Q1 2025. Consensus earnings per share (EPS) estimate stands at -$1.31, reflecting acquisition-related charges.

Analysts expect Q1 2026 revenue of $16.43 billion, a 15% increase from $14.25 billion in Q1 2025. Consensus EPS (earnings per share) is projected at $4.57, up from $4.20 last year.

Analysts expect Q1 2026 EPS of $4.41, up 18% year-over-year from $3.73. Consensus revenue forecast stands at $8.26 billion, reflecting 14% growth.

Analysts expect Q1 2026 revenue of $17.78 billion, up 39.7% year-over-year from $12.73 billion in Q1 2025. Consensus non-GAAP EPS forecast at $7.26, reflecting robust demand for key products.

Analysts expect Q2 FY2026 revenue of approximately $109.5 billion, up about 15% year-over-year from $95.4 billion. Consensus EPS forecast stands at $1.94, reflecting roughly 17% growth from the prior year's $1.65.

Analysts forecast Q1 2026 revenue of $12.71 billion, reflecting 4.1% year-over-year (YoY) growth from $12.2 billion in Q1 2025. Consensus diluted earnings per share (EPS) stands at $3.69, a slight 0.8% increase from $3.66 reported last year.

GSK plc reported Q1 2026 total sales of £7.6 billion, up 5% at constant exchange rates (CER), slightly ahead of consensus expectations. Core earnings per share (EPS) reached 46.5p, a 9% increase at CER, surpassing analyst estimates of around 43.5p.

UBS Group AG posted a first-quarter 2026 net profit attributable to shareholders of $3.0 billion, up 80% from the prior year and well above consensus estimates of around $2.3 billion. Return on Common Equity Tier 1 capital (RoCET1) reached 16.8%, with an underlying figure of 17.0%.

Analysts anticipate second quarter fiscal 2026 revenue of approximately $10.6 billion, down slightly year-over-year (YoY) from $10.8 billion in the prior-year period. Consensus non-GAAP earnings per share (EPS) estimate stands at $2.57, within the company's guidance range of $2.45 to $2.65.

Banco Santander reported underlying profit of €3.6 billion for Q1 2026, up 12% year-over-year (YoY) and beating analyst consensus of €3.5 billion. Total revenue rose 4% YoY to €15.1 billion, exceeding expectations of €15.0 billion, driven by 4% growth in net interest income (NII) and 6% in net fee income.

Analysts project Q1 2026 revenue of approximately $7.1 billion, implying about 48% year-over-year growth. Consensus EPS estimate stands at $0.95, reflecting over 50% growth from Q1 2025's adjusted $0.63.

TotalEnergies SE reported adjusted net income of $5.4 billion for Q1 2026, up 29% from Q1 2025 and 41% from Q4 2025. Revenue reached $49.5 billion, surpassing consensus estimates around $46.8 billion.

Consensus estimates call for Q3 FY2026 revenue of approximately $3.37 billion, in line with the company's guidance midpoint of $3.35 billion. Non-GAAP earnings per share (EPS) expected at $9.16, edging above the guided midpoint of $9.08.

AstraZeneca reported Q1 2026 total revenue of $15.3 billion, up 8% at constant exchange rates (CER, adjusting for currency fluctuations), beating consensus estimates around $14.8 billion. Core earnings per share (EPS) rose 5% to $2.58 at CER, amid a 12% increase in core operating profit.

Shares of CRML are declining approximately 9.52% on Tuesday, April 28, 2026, falling from a prior close of $14.45 to approximately $13.08, as the initial euphoria surrounding Monday's blockbuster $835 million acquisition of European Lithium Ltd. is replaced by sober reassessment of dilution risk, deal closing complexity, and the structural sustainability of a 25% single-session price surge driven largely by retail momentum.

CRML stock surged +117% over the past 30 days, driven primarily by the announcement of a $835 million acquisition of European Lithium and a $60 million private placement. Over the past quarter, shares declined -15% amid high volatility, reflecting an initial rally on a Saudi joint venture term sheet followed by a sharp pullback.